ArticleScientific reports2026
Modifying VEGF-A mRNA by combinatorial optimization to enhance therapeutic efficacy for myocardial infarction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vascular endothelial growth factor A (VEGF-A) is a highly specific endothelial cell mitogen that critically regulates angiogenesis and vascular network formation. While VEGF-A mRNA administration enables dose-dependent protein expression and therapeutic angiogenesis without genomic integration, unmodified mRNA suffers from rapid degradation and inherent immunogenicity, which substantially limits its therapeutic potential. In this study, we designed and synthesized a combinatorially optimized modified VEGF-A mRNA construct, designated Km10566, engineered to enhance translational efficiency and reduce immunogenicity through strategic incorporation of modified nucleosides. In vitro transcription (IVT) assays demonstrated that Km10566 yields substantially increased VEGF-A protein expression compared to unmodified counterparts. Following intracardiac administration in a rat model of myocardial infarction, a single dose of Km10566 formulated in citrate saline buffer significantly improved left ventricular ejection fraction (LVEF) and reduced myocardial fibrosis at 21 days post-treatment. Pharmacodynamic analysis confirmed sustained VEGF-A expression and enhanced vascularization in the ischemic myocardium. These findings establish Km10566 as a promising therapeutic candidate for cardiac repair and support its further evaluation in preclinical and clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.